New drug for TED reports Ph II results
Immunovant reports phase IIa results for IMVT-1401. My thoughts on results: Small patient study. Proptosis efficacy is sub-optimal to Tepezza. Diplopia results are similar. Drug delivery is sub-cutaneous vs infused for Tepezza.
Link to story below.
https://immunovant.com/immunovant-announces-positive-clinical-results-from-ongoing-phase-2a-proof-of-concept-study-of-imvt-1401-a-novel-investigational-anti-fcrn-antibody-delivered-by-subcutaneous-injection-in-thyroid-eye/